CCXA

ChemoCentryx is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small molecule therapeutics that target the chemokine system. The company's lead product, Tavneos (avacopan), is a first-in-class complement C5a receptor inhibitor approved for the treatment of ANCA-associated vasculitis. ChemoCentryx utilizes its proprietary EnabaLink drug discovery engine to identify selective inhibitors of chemokine and complement receptors involved in inflammatory disorders, autoimmune diseases, and cancer. In October 2022, the company was acquired by Amgen for approximately $3.7 billion, integrating its specialized immunology and nephrology portfolio into Amgen's broader therapeutic pipeline.